As shown here, PI3K/AKT signaling is further enhanced by loss of PTEN and PIPP over and above that observed with loss of an individual PI-phosphatase in breast cancer cells, and future screening for these changes in breast cancer cohorts may contribute to improved patient selection for treatments. This evidence concerns the gene AKT1 and breast carcinoma.